BESPONSA safety tracked in over 400 leukemia patients
NCT ID NCT05923112
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the safety of the drug BESPONSA in 421 people with a type of blood cancer called acute lymphocytic leukemia that had come back or stopped responding to treatment. All participants received BESPONSA as prescribed by their doctor. Researchers tracked side effects, especially liver problems, low blood cell counts, infections, and bleeding, for up to a year after starting the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BESPONSA (inotuzumab ozogamicin)
What this could lead to
If successful, this study could confirm the safety profile of BESPONSA for treating relapsed or refractory acute lymphocytic leukemia.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove effectiveness. Results may not apply outside Japan.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan